Bristol Myers expects to launch 16 new products through 2030 - CEO
Reuters
Published Jan 08, 2024 12:43PM ET
(Reuters) - Bristol Myers (NYSE:BMY) Squibb CEO Christopher Boerner said on Monday the drugmaker expects to add 16 new products to its portfolio by the end of the decade.
The drugmaker said it would focus on licensing, partnerships and bolt-on purchases as opposed to large acquisitions after signing two multi-billion dollar deals last month.
"Our focus is to continue to enrich this portfolio first and foremost, by advancing our internal pipeline and where it makes sense strategically and financially through business development," Boerner said at the JPMorgan Healthcare conference.
In December, Bristol Myers bought Karuna Therapeutics (NASDAQ:KRTX) for $14 billion, gaining a promising new type of antipsychotic medicine. It was followed by a $4.1 billion buyout of RayzeBio, bolstering its cancer drug business.
It acquired cancer drugmaker Mirati Therapeutics (NASDAQ:MRTX) for up to $5.8 billion in October, diversifying its oncology business and adding drugs it hopes can help offset expected lost revenue from patent expirations later this decade.
Bristol Myers reiterated its long-term forecast of greater than $10 billion of new-product sales in 2026.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.